Stocks Health care RPRX
NASDAQ · Health careRoyalty Pharma plc (RPRX)
Royalty Pharma plc brought in $2.6B of revenue over the twelve months to September 30, 2026, up 11.4% from a year earlier. Net income was $672.5M, a net margin of 25.7%. At September 30, 2026 it held $513.7M in cash against $8.6B of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 4, 2026.
Key facts about Royalty Pharma plc
- Net worth
- Royalty Pharma plc has a market value (market cap) of $39.8B at the latest share price, and shareholders' equity of $9.8B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $2.4B (+5.1% year on year), with net income of $770.9M. Over the 12 months to September 30, 2026: revenue $2.6B, net income $672.5M.
- Cash flow
- In fiscal 2025 operations brought in $2.5B of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 4, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Royalty Pharma plc's next report is expected around February 10, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
- Dividend
- Royalty Pharma plc paid dividends of $0.84 per share in fiscal 2024.
What Royalty Pharma plc does
Royalty Pharma plc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker RPRX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $2.4B | $770.9M | $1.78 | n/a |
| 2024 | $2.3B | $859M | $1.91 | n/a |
| 2023 | $2.4B | $1.1B | $2.53 | n/a |
| 2022 | $2.2B | $42.8M | $0.10 | n/a |
| 2021 | $2.3B | $619.7M | $1.49 | n/a |
| 2020 | $2.1B | $975M | $1.32 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where RPRX ranks in Health care
Dividends
Royalty Pharma plc paid $0.84 per share in fiscal 2024.
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2024 | $0.84 | n/a | n/a |
| 2023 | $0.80 | n/a | n/a |
| 2022 | $0.76 | n/a | n/a |
| 2021 | $0.68 | n/a | n/a |
| 2020 | $0.30 | n/a | n/a |
Latest SEC filings
What Royalty Pharma plc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026Passive stake changed SCHEDULE 13G/A
- November 4, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 13% to $690.1M versus the same quarter last year; diluted EPS $0.32 versus $0.66.
- November 4, 2026
- August 17, 2026Activist stake changed SCHEDULE 13D/A
- August 14, 2026Form 13F-NT filing 13F-NT
- August 5, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 16% to $674.1M versus the same quarter last year; diluted EPS $0.04 versus $0.07.
- August 5, 2026
- June 16, 2026Activist stake changed SCHEDULE 13D/A
- June 4, 2026
- May 28, 2026
Insider trades
What the people running Royalty Pharma plc did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $13M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 6, 2026 | Coyne Terrance P.EVP & CFO | Exercised optionsindirect | 150,000 | - |
| November 6, 2026 | Coyne Terrance P.EVP & CFO | Exercised optionsindirect | 100,000 | - |
| November 6, 2026 | Urist MarshallEVP, Research & Investments | Exercised optionsindirect | 150,000 | - |
| November 4, 2026 | Legorreta Pablo G.CEO, Chairman of the Board, Director | Received as pay | 42,209 | - |
| November 4, 2026 | Hite ChristopherEVP & Chairman, Partnering | Received as payindirect | 7,122 | - |
| November 4, 2026 | Coyne Terrance P.EVP & CFO | Received as payindirect | 7,122 | - |
| November 4, 2026 | Urist MarshallEVP, Research & Investments | Received as pay | 5,341 | - |
| October 5, 2026 | Urist MarshallEVP, Research & Investments | Soldpre-planned (10b5-1) | 4,126 | $235.6K |
Who owns RPRX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Legorreta G. Pablo13D, may seek influence with 1 related filers | 18.73% | August 17, 2026 |
| R & H Trust Co. (Guernsey) Limited13D, may seek influence with 8 related filers | 9.2% | July 29, 2024 |
| Capital International Investors13G, passive | 8.8% | May 14, 2026 |
| Fmr LLC13G, passive with 1 related filers | 6.5% | November 5, 2025 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 643 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Morgan Stanley | 42,931,597 | -640,036 |
| Capital International Investors | 35,273,770 | +268,034 |
| BlackRock, Inc. | 27,832,977 | +1,925,232 |
| Fmr LLC | 24,513,814 | -638,428 |
| State Street Corp | 12,338,229 | +1,348,378 |
| Swedbank AB | 10,726,608 | -860,085 |
| Baillie Gifford & Co | 10,015,578 | -6,140,099 |
| Capital World Investors | 9,517,337 | +1,480,623 |
| Geode Capital Management, LLC | 8,058,048 | +188,416 |
| Caledonia (Private) Investments Pty Ltd | 5,775,851 | -1,392,548 |
| Norges Bank | 5,336,084 | new |
| Vanguard Capital Management LLC | 4,826,617 | +294,731 |
| Northern Trust Corp | 4,718,859 | +910,124 |
| Royal London Asset Management Ltd | 4,319,595 | +511,242 |
| Aqr Capital Management LLC | 4,305,412 | +523,374 |
| Invesco Ltd. | 4,232,577 | +480,178 |
| Bank of America Corp | 4,149,422 | +653,576 |
| Legal & General Group Plc | 3,800,504 | +437,632 |
| Amundi | 3,723,864 | +635,091 |
| Victory Capital Management Inc | 3,682,932 | -170,876 |
Insiders
12 insiders reported holding 2,367,194 shares in total, about $163.7M at the last price.
| Holder | Shares |
|---|---|
| Legorreta Pablo G.CEO, Chairman of the Board, Director | 1,350,029 |
| Hite ChristopherEVP & Chairman, Partnering | 300,723277,523 held indirectly |
| Norden GregoryDirector | 196,348 |
| Urist MarshallEVP, Research & Investments | 155,341150,000 held indirectly |
| Coyne Terrance P.EVP & CFO | 100,000100,000 held indirectly |
| Bassler Bonnie LDirector | 79,823 |
| Love Ted WDirector | 58,393 |
| Engelbert Catherine M.Director | 55,673 |
| Hodgson David CDirector | 37,873 |
| Coric VladDirector | 15,343 |
Questions about RPRX
What does Royalty Pharma plc do?
Royalty Pharma plc is a company in the Health care sector, listed on NASDAQ as RPRX. Its shares trade on NASDAQ under the ticker RPRX.
What is Royalty Pharma plc's net worth?
Royalty Pharma plc has a market value (market cap) of $39.8B at the latest share price, and shareholders' equity of $9.8B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Royalty Pharma plc profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $672.5M on revenue of $2.6B, a net margin of 25.7%.
How much revenue does Royalty Pharma plc make?
Over the twelve months to September 30, 2026 Royalty Pharma plc reported revenue of $2.6B. That is 11.4% more than a year earlier.
When did Royalty Pharma plc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 4, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the insider trade from November 6, 2026.
When is Royalty Pharma plc's next earnings report?
Royalty Pharma plc's next report is expected around February 10, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Does Royalty Pharma plc pay a dividend?
Yes. Royalty Pharma plc paid dividends of $0.84 per share in fiscal 2024.
Similar companies
Compare RPRX with
Follow RPRX
Get an email when Royalty Pharma plc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Royalty Pharma plc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.